Thermo Fisher to Acquire Olink for $3.1B
Ticker: TMO · Form: 8-K · Filed: Jul 10, 2024 · CIK: 97745
| Field | Detail |
|---|---|
| Company | Thermo Fisher Scientific Inc. (TMO) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, life-sciences, proteomics
TL;DR
TMO buying Olink for $3.1B to boost proteomics game.
AI Summary
Thermo Fisher Scientific Inc. announced on July 10, 2024, that it has entered into a definitive agreement to acquire Olink Holding AB for approximately $3.1 billion. The acquisition is expected to close in the second half of 2024, subject to customary closing conditions and regulatory approvals.
Why It Matters
This acquisition significantly expands Thermo Fisher's capabilities in proteomics, a rapidly growing field in life sciences research and diagnostics.
Risk Assessment
Risk Level: medium — The acquisition is subject to regulatory approvals and customary closing conditions, which could delay or prevent its completion.
Key Numbers
- $3.1B — Acquisition Price (Thermo Fisher Scientific is acquiring Olink Holding AB for this amount.)
Key Players & Entities
- Thermo Fisher Scientific Inc. (company) — Acquiring company
- Olink Holding AB (company) — Target company
- $3.1 billion (dollar_amount) — Acquisition price
- July 10, 2024 (date) — Announcement date
- second half of 2024 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind Thermo Fisher's acquisition of Olink?
The acquisition is expected to expand Thermo Fisher's capabilities in proteomics, a key area in life sciences research and diagnostics.
What is the total value of the transaction?
The definitive agreement is for approximately $3.1 billion.
When is the acquisition expected to be completed?
The acquisition is expected to close in the second half of 2024.
Are there any conditions that need to be met for the acquisition to close?
Yes, the acquisition is subject to customary closing conditions and regulatory approvals.
What is Olink Holding AB's primary business area?
Olink Holding AB is involved in proteomics, as indicated by Thermo Fisher's strategic interest in expanding its capabilities in this field.
Filing Stats: 660 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-07-10 16:36:35
Key Financial Figures
- $1.00 — ange on which registered Common Stock, $1.00 par value TMO New York Stock Exchan
Filing Documents
- form8-k.htm (8-K) — 58KB
- 0000950157-24-000978.txt ( ) — 318KB
- tmo-20240710.xsd (EX-101.SCH) — 7KB
- tmo-20240710_def.xml (EX-101.DEF) — 23KB
- tmo-20240710_lab.xml (EX-101.LAB) — 36KB
- tmo-20240710_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 22KB
01
Item 8.01 Other Events. On July 10, 2024, Thermo Fisher Scientific Inc. (" Thermo Fisher ") issued a press release announcing the expiration and results of the previously announced tender offer by Orion Acquisition AB, a direct, wholly owned subsidiary of Thermo Fisher, to purchase all of the outstanding common shares and all of the outstanding American Depositary Receipts, each representing one common share, of Olink Holding AB (publ). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated July 10, 2024 (filed as Exhibit (a)(5)( W) to the Registrant's Schedule TO-T/A filed July 10, 2024 File No. 005-93360 and incorporated in this document by reference). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERMO FISHER SCIENTIFIC INC. Date: July 10, 2024 By: /s/ Michael A. Boxer Name: Michael A. Boxer Title Senior Vice President and General Counsel